@TevaUSA

We’re a leading innovative biopharmaceutical company, enabled by a world-class generics business. Guidelines: https://xitter.cf/t.co/sOC1rpJ9tr

 United States
tevausa.com
Joined August 2010
  • Tweets3.4K
  • Following1K
  • Followers10.8K
1.7KMedia
BREAKING: The FDA has granted approval of our new schizophrenia long-acting treatment option. Read more from today’s announcement here: ow.ly/9sjW50ZWenA $TEVA
3
1
14
1,499
New long-term maintenance data presented at #UEGWeek, evaluating our investigational treatment option for ulcerative colitis (UC) and Crohn’s disease (CD). See press release here: ow.ly/LmkO50ZZijG #TevaPharm $TEVA @sanofi
3
262
#News: Research is shedding light on Tourette syndrome in pediatric patients and potential treatment options, with new clinical data presented at #MDSCongress and a review published in @JChildNeurol See more: tevausa.com/news-and-media/p…
2
339
Partnering to improve patient access to life changing medicines: Teva and @SamsungBioepis expand strategic partnership to advance up to six potential biosimilar candidates. Learn more: tevapharm.com/news-and-media…
1
287
BREAKING: Teva receives FDA approval for a new biosimilar treatment to help prevent skeletal-related events in people with certain cancers or bone metastases from solid tumors, and to treat hypercalcemia of malignancy: bit.ly/3VE7xdf $TEVA #PivotToGrowth
1
1
4
2,351
At #PsychCongress2026, Teva presents new studies within our innovative medicines portfolio, covering the latest research and real-world evidence in schizophrenia, bipolar I disorder and tardive dyskinesia. Read the press releases here: ow.ly/cPy250ZNnuO
1
350
Today, we are announcing the launch of LongActingImpact.com, a resource built to provide healthcare professionals with practical guidance and insights on utilizing long-acting injectables (LAIs) for #schizophrenia treatment. Learn more: ow.ly/xAbW50ZOgfh
4
302
Teva Pharmaceuticals retweeted
NYSE 🏛
@NYSESep 14
The NYSE welcomes @TevaUSA to celebrate its first day of trading ordinary shares! $TEVA xitter.cf/i/broadcasts/1qKVmybmL…
0:00

NYSE 🏛

Teva Pharmaceutical (NYSE: TEVA) Rings The Closing Bell

5
6
76
794,154
Exciting #news: Teva achieves Investment Grade from all three leading credit rating agencies, as @SPGlobalRatings joins @moodysratings and @FitchRatings in upgrading Teva’s rating, recognizing the progress we have made to strengthen our financial profile and execute our Pivot to Growth strategy. Learn more: tevapharm.com/news-and-media…
1
1
6
291
#Breaking: Teva announces positive topline results from phase 2a study in celiac disease for its anti-il-15 antibody, further validating its pipeline-in-a-product potential. Join the webcast today at 8:00 am ET: ir.tevapharm.com/Events-and-… Read the press release: tevapharm.com/news-and-media…
1
3
9
452
The @US_FDA has accepted Teva’s NDA and granted Priority Review for a potential new treatment option for pediatric patients living with #TouretteSyndrome. Learn more here: ow.ly/XwzB50ZBqvX #PivotToGrowth $Teva
1
6
497
Teva Pharmaceuticals retweeted
Squawk on the Street
@SquawkStreetJul 29
"It's a pipeline that not only meets unmet medical need – we believe it has a high probability of being successful." @TevaUSA CEO Richard Francis explains why the company's developing its own drugs instead of sticking strictly with generics: cnbc.com/video/2026/07/29/wa…

Watch CNBC's full interview with Teva Pharmaceuticals CEO Richard Francis

Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business, and more.

cnbc.com
1
1
4
5,272
Our Q2 2026 earnings call is starting in 30 minutes. Join CEO Richard Francis live to hear about Teva's business performance and plans ahead. ow.ly/S0cL50Zu8eo Forward-looking statements are subject to the cautionary note included in our Q2 2026 press release. #QuarterlyResults #Earnings $Teva
5
3
383
We are reporting our Q2 2026 financial results, as we continue our transformation into a leading biopharma company tevapharm.com/news-and-media… Forward-looking statements are subject to the cautionary note included in our Q2 2026 press release. #QuarterlyResults #Earnings $Teva
1
1
3
594
Tune in to our Q2 2026 earnings call with CEO Richard Francis and the Teva leadership team on Wednesday, July 29. Save the date: ow.ly/2cqp50ZrfPm #QuarterlyResults #Q2Results #Earnings $Teva Forward-looking statements are subject to the cautionary note included in our Q2 2026 press release.
2
426
🆕Results from RELIEVE UCCD - efficacy and safety of duvakitug in patients with Crohn's disease or ulcerative colitis UC - thelancet.com/journals/langa… CD - thelancet.com/journals/langa… #GITwitter #MedTwitter
1
12
20
3,121
An exciting moment: @LancetGastroHep published peer-reviewed analyses from our Phase 2b study for an investigational treatment for #UlcerativeColitis and #CrohnsDisease. Read more: thelancet.com/journals/langa… thelancet.com/journals/langa…
1
3
5
254
Teva to advance its anti-IL-15 antibody, designed for quarterly dosing, into Phase 2b development in vitiligo, following encouraging Phase 1b results. Learn more here: bit.ly/4ynYagW
1
2
4
372
As a leader in neuroscience, we are committed to advancing innovative treatments that may help address critical unmet needs for patients living with complex conditions. Today, Teva announced the submission of a New Drug Application (NDA) to the U.S. FDA for an investigational therapy for pediatric Tourette syndrome. Learn more: ow.ly/LwKt50ZerWu #TevaPharm $Teva
4
3
4
381
Load more